Comparative Pharmacology
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus THYROLAR 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus THYROLAR 3.
LEVOTHYROXINE SODIUM vs THYROLAR-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic T4 hormone that is deiodinated to T3, which binds to thyroid hormone receptors in the nucleus, regulating gene transcription and increasing metabolic rate.
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
Initial adult dose: 25-50 mcg orally once daily, titrated by 12.5-25 mcg every 6-8 weeks based on TSH. Usual maintenance: 1.6 mcg/kg/day. Route: oral; IV dose is 50% of oral dose.
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
None Documented
None Documented
6-7 days (euthyroid); prolonged in hypothyroidism (9-10 days) and shortened in hyperthyroidism (3-4 days).
Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged.
Renal (approximately 50% as unchanged drug and conjugates); fecal (biliary excretion of conjugates, ~20-30%); minor pulmonary and dermal routes.
Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%)
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone